FUSEN PHARM (01652) announced that the company's self-developed "Metformin Empagliflozin Tablets (I)" has received marketing approval from China's National Medical Products Administration. The drug is approved for the treatment of the following condition: in combination with diet and exercise, it is indicated for adult patients with type 2 diabetes who are currently receiving empagliflozin and metformin hydrochloride treatment, to improve glycemic control in these patients.

"Metformin Empagliflozin Tablets (I)" is a combination formulation composed of metformin hydrochloride and empagliflozin. The pharmacological mechanisms are as follows: Metformin reduces hepatic glucose production, inhibits intestinal glucose absorption, and increases peripheral glucose uptake and utilization, thereby improving insulin sensitivity through enhanced peripheral glucose uptake and utilization. Empagliflozin is an SGLT2 inhibitor that reduces renal glucose reabsorption, lowers the renal glucose threshold, and promotes glucose excretion through urine. The two components have synergistic mechanisms and demonstrate superior glycemic control compared to conventional single-agent formulations.

The directors believe that Metformin Empagliflozin Tablets (I) represents another important product for the group, further enriching the company's product pipeline in the diabetes treatment field. This product will provide more treatment options for diabetes patients.